According to filings with the U.S. Securities and Exchange Commission, Ingenia Therapeutics is raising up to $25,000,000.00 in new funding. Sources indicate that as part of senior management President, Sangyeul Han played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ingenia Therapeutics
INGENIA Therapeutics is a biotech startup company located near Kendall Square, Cambridge, MA, strives to develop durable best-in-class therapeutic antibodies, restoring dysfunctional microvessels into their healthy state in multiple ophthalmic diseases. We are committed to the discovery and development of advanced therapeutics for patients afflicted by inflamed and leaky blood vessels. We use our deep knowledge and commitment to endothelial biology to innovate and find new solutions where none exist. We focus on the treatment of damaged small vessel-associated diseases with high unmet clinical needs. INGENIA builds on strategic research partnerships with major pharmaceutical companies for research and development activities to deliver human proof of concept studies. We aim to be a global leader in developing next-generation therapeutics to protect and restore the microvasculature.

To learn more about Ingenia Therapeutics, visit http://ingeniatx.com/
Company Linkedin Page: https://www.linkedin.com/company/ingenia-therapeutics/

Contact:
Sangyeul Han, President
781-491-9005
https://www.linkedin.com/in/sangyeul-han-49517b20/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.